Sun Kang sold $642K of AMPX

Sun Kang sold 62,101 shares of Amprius Technologies, Inc. (AMPX) at $10.34 ($0.64M total) on 2026-08-21.

Original reporting
SEC EDGAR · Sun Kang
Published Aug 25, 2026, 9:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 25, 2026, 9:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AMPX
Neutral
high confidence
Mentioned
$AMPX
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AMPXNeutralLow
01

Why it matters

The disclosed sale is modest and unlikely to affect market perception of AMPX.

02

Market read

Routine insider sale with limited trading relevance.

03

What to watch

Potential upcoming financing needs or personal liquidity needs for the director.

Relevance 5/10Novelty 4/10Timing: post-market filing

Background

SEC Form 4 filing discloses insider transactions; used by traders to gauge insider sentiment.

Company-level read

Ticker impact

$AMPXNeutralHigh confidence
Context

Director Sun Kang sold 62,101 shares for $642,186, reducing his stake to 1,218,397 shares.

Expected impact

No significant price impact expected.

Evidence & confidence

The sale size is small relative to float and market cap; typical for insiders.

Market effects

None significant; insider sale does not affect sector trends.

None.

None.

Counterpoint

If insider selling signals concerns, a short position could be considered, but evidence is weak.

Key entities

  • Amprius Technologies, Inc.

    US-listed battery technology company (ticker AMPX).

  • Sun Kang

    Director of Amprius Technologies.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AMPXMedAI 8/10

Amprius (AMPX) Q3 2026 Earnings Call Transcript

Amprius reported Q3 2026 revenue of $39.1M, up 83% YoY, raising its full-year target to $145M. The company introduced SiCore 500 cells for aviation and secured a $75M U.S. defense contract. Amprius expanded into maritime vehicles and partnered with U.S. manufacturers for NDAA-compliant production.

$AMPXMedAI 8/10

Amprius Technologies Q3 Earnings Call Highlights

Amprius reported a Q3 net loss of $3.5M, with adjusted EBITDA at -$1M. The company maintained its full-year gross margin forecast of 28% and expects Q4 sales of $43.3M. Amprius is expanding manufacturing to meet demand, with a $75M contract for a U.S. battery production line. It also introduced new products for aviation and deep-sea applications, ending Q3 with $60.7M in cash.

$AMPXHigh

Amprius Technologies falls 7% on third quarter earnings miss

Amprius Technologies (NYSE:AMPX) reported Q3 earnings missing estimates with a loss of $0.02 per share, though revenue of $39.1M beat expectations. Shares fell 7.7% after-hours. The company raised its full-year 2026 revenue outlook to $145M, above analyst forecasts. Gross profit rose 217% YoY to $10.5M, with gross margin improving to 27%. Amprius secured a $75M U.S. Department of War contract and introduced a new battery cell.

$AMPXMed

Amprius Technologies Reports Third Quarter 2026 Financial Results and Recent

Amprius Technologies, Inc. (AMPX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Amprius Technologies Reports Third Quarter 2026 Financial Results and Recent Business Highlights • Q3 2026 revenue increased 83% year-over-year to $39.1 million • Net loss of $3.5 million, a 10% year-over-year improvement • Increasing 2026 revenue outlook to $145 mil

$AMPXHigh

AMPX Stock Jumps As Defense Deals Supercharge Growth Story

Amprius Technologies Inc. (NYSE: AMPX) shares rose 8.38% on October 21, 2026, driven by U.S. Department of War funding and a partnership with Caminus for battery production. The company secured $75M in funding for a high-energy-density cell plant, with revenue growth but negative margins. Canaccord Genuity initiated coverage with a Buy rating and $14 price target.